Two Onc Docs
Acute Myeloid Leukemia (AML) 2024 x Dr. Catherine Lai Part 2
Jun 24, 2024
Dr. Catherine Lai from UPenn discusses AML treatment options, including chemotherapy regimens based on core binding factors, variations in toxicity, and advancements like Gemtuzumab. She also explores recovery strategies, repeatable marrow biopsies, and different treatment approaches based on risk categories and patient fitness levels. The podcast ends with key takeaways on AML diagnosis criteria, induction regimens, specific treatment options for mutations, and the importance of seeking feedback.
17:29
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- For fit AML patients, treatment regimens include 7 and 3 with specific agents based on genetic mutations.
- Response assessment guides consolidation therapy and maintenance treatments, emphasizing personalized approaches for AML management.
Deep dives
Treatment Options for Fit Patients with AML
For fit patients with AML, fitness is now determined by factors beyond chronologic age. Patients with core-binding factor AML receive a standard regimen of 7 and 3 along with GEMtuzumab. For patients not in the favorable or intermediate risk group, the standard remains 7 and 3 with Doxorubicin or Idarubicin, with consideration for FLT3 mutation adding agents like Midostaurin or Quizartinib.
